Fragile X premutation screening in women with premature ovarian failure.
about
The fragile-X premutation: a maturing perspective.Microdeletions in FMR2 may be a significant cause of premature ovarian failureThe genetic basis of female reproductive disorders: etiology and clinical testingThe unstable repeats--three evolving faces of neurological diseaseIntermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age.Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failureThe X chromosome and ovarian failure.IVF for premature ovarian failure: first reported births using oocytes donated from a twin sister.Advances in understanding the molecular basis of FXTASFMR1 premutation is an uncommon explanation for premature ovarian failure in Han Chinese.Premature ovarian failure: etiology and prospects.Elevated levels of FMR1 mRNA in granulosa cells are associated with low ovarian reserve in FMR1 premutation carriers.Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutationsPremature ovarian failure in the fragile X syndrome.Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population.Ovarian function in girls and women with GALT-deficiency galactosemiaThe FMR1 gene and fragile X-associated tremor/ataxia syndrome.Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiencyA novel assay for evaluating fragile X locus repeatsChromatin changes in the development and pathology of the Fragile X-associated disorders and Friedreich ataxia.Dynamics of the ovarian reserve and impact of genetic and epidemiological factors on age of menopause.EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disordersSomatic expansion in mouse and human carriers of fragile X premutation alleles.Presence or absence of menstruation in young girls.Trisomic pregnancy and intermediate CGG repeat length at the FMR1 locusThe role of genetic and autoimmune factors in premature ovarian failure.Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation womenThe fragile X continuum: new advances and perspectives.Molecular pathogenesis of fragile X-associated tremor/ataxia syndromeFragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency.Chromosomal abnormalities in women with premature ovarian failure.Distribution of FMR1 and FMR2 Repeats in Argentinean Patients with Primary Ovarian Insufficiency.Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences.FMR1 gene mutation screening by TP-PCR in patients with premature ovarian failure and fragile-X.Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function.[Premature ovarian failure: present aspects].The significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal and intermediate range in women with primary ovarian insufficiency.Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene.Association between idiopathic premature ovarian failure and fragile X premutation.
P2860
Q24533443-77DD6B40-CC25-42D0-AA5D-AE5BCDF6FABFQ24681930-3AAD800B-6AFB-436E-9FA7-568FCF981278Q26865875-5CBB6B98-1901-41DC-B481-BC43420AE0FBQ27025923-A4071529-AAC5-45C2-8A6F-EFF525AC9EDFQ33786496-525B9D81-0FFA-4660-AB0B-647179878DD0Q33787119-63C5C628-0FE4-4C88-99BF-553D8FE07759Q33808375-FF720D57-FB80-4853-99D4-61A5B508438CQ33818708-35FF74A1-1510-478C-905E-257328EE2CE1Q33871325-CA517236-1691-4B0F-BBB1-EF7E01F13F6FQ33933573-904DC921-EE4C-407E-A220-FB984CE565CCQ34081134-43737BEA-3CF5-41C3-A48C-752497ACB91AQ34083509-13A7885A-DE32-4AC1-A69A-D566FB75588CQ34145023-EBD0DE67-27AE-4729-A6DE-40C0B67ECCECQ34306135-EBBC64B3-D7D7-44C2-8D78-DA8D206580CEQ34388858-736D04F9-F9D8-4EEC-ABFA-E9FBBCC42327Q34714428-EE200058-CDC0-4EDF-BDA7-F807063D214FQ35061671-47FD0C18-9FAA-4D5A-9AAB-AEE51524DAE5Q35230078-E1856416-80CE-417E-8CCB-1E08E37F8BCFQ35356435-60649F39-F632-47B2-A93B-6AB11CF7825AQ36016607-71F1DCB0-D2CA-4439-9F1E-07B0E15C546AQ36282786-F4CE2A16-A515-4A2F-B042-72612475134AQ36338209-93236E05-E341-43FF-85FB-2BE9BA6E504BQ36472667-93758CBE-442F-491D-B57E-AC2D83662E88Q36739159-FD0C6E35-79F8-47AC-9348-DB9AD74D3C7DQ36749500-34B7E2E9-91A3-4782-831F-FD829F0EFC2BQ36875089-0A24F3C8-C1A8-4630-950B-A0F561DF220AQ37058031-BF5B33FA-B3ED-474F-8CF6-1AEBF594C243Q37150380-2D98FECA-7C4A-4000-9C6F-798554311FE1Q37455479-BEDF77F3-4633-4777-9FD3-1378051D5986Q37524454-FDE231AA-E3CB-4B06-8B2D-190CD2C0DC8DQ37555606-3EC635F5-F6F6-4D25-8EAD-19C64CF27ECAQ37775022-4AA2D71F-A165-4695-B3F6-D405A55F3D4FQ38622358-A377FBCB-121C-4167-AAB9-72D8D6215F60Q44191652-3DBAEC78-F979-44CF-9AD7-0417E6504F27Q44250695-E34AB1A3-A71E-4736-B59B-BC5B0B91E957Q44357532-3534FADE-96D3-4E66-BFDD-1CF430069ECBQ46952708-C8058532-95D9-4905-9863-012BCB1DAF83Q50644642-31FBC9FD-4AA9-4251-808E-A859BD53EDD7Q51633143-173C7495-67D3-408E-A72E-0EF6DC23BE87Q51978995-83A8CDB3-527B-4F4F-89CD-EB711EE9E69A
P2860
Fragile X premutation screening in women with premature ovarian failure.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Fragile X premutation screening in women with premature ovarian failure.
@en
Fragile X premutation screening in women with premature ovarian failure.
@nl
type
label
Fragile X premutation screening in women with premature ovarian failure.
@en
Fragile X premutation screening in women with premature ovarian failure.
@nl
prefLabel
Fragile X premutation screening in women with premature ovarian failure.
@en
Fragile X premutation screening in women with premature ovarian failure.
@nl
P2093
P356
P1433
P1476
Fragile X premutation screening in women with premature ovarian failure.
@en
P2093
P304
P356
10.1093/HUMREP/13.5.1184
P407
P577
1998-05-01T00:00:00Z